JPWO2021216678A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021216678A5 JPWO2021216678A5 JP2022564370A JP2022564370A JPWO2021216678A5 JP WO2021216678 A5 JPWO2021216678 A5 JP WO2021216678A5 JP 2022564370 A JP2022564370 A JP 2022564370A JP 2022564370 A JP2022564370 A JP 2022564370A JP WO2021216678 A5 JPWO2021216678 A5 JP WO2021216678A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- angiotensin
- antioxidant
- linked
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 239000003963 antioxidant agent Substances 0.000 claims 12
- 230000003078 antioxidant effect Effects 0.000 claims 12
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 6
- 229960003073 pirfenidone Drugs 0.000 claims 6
- 230000036454 renin-angiotensin system Effects 0.000 claims 6
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims 5
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 4
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Claims (16)
第１の抗酸化物質に連結したピルフェニドン（ＰＦＤ）を含むレニン－アンジオテンシン系（ＲＡＳ）モジュレーターであり、前記第１の抗酸化物質がテンポールを含むモジュレーター；及び
薬学的に許容される担体を含む、医薬組成物。 1. A pharmaceutical composition for treating a subject in need thereof, comprising:
A pharmaceutical composition comprising: a renin-angiotensin system (RAS) modulator comprising pirfenidone (PFD) linked to a first antioxidant, said first antioxidant comprising tempol ; and a pharma- ceutical acceptable carrier.
前記レニン－アンジオテンシン系モジュレーターが、アンジオテンシン受容体ブロッカー（ＡＲＢ）、アンジオテンシン（１－７）、ＨＭＧ－ＣｏＡ還元酵素阻害剤及びアンジオテンシン変換酵素（ＡＣＥ）阻害剤のうち少なくとも１つをさらに含む、医薬組成物。 2. The pharmaceutical composition according to claim 1 ,
The pharmaceutical composition, wherein the renin-angiotensin system modulator further comprises at least one of an angiotensin receptor blocker (ARB), an angiotensin (1-7), an HMG-CoA reductase inhibitor, and an angiotensin converting enzyme (ACE) inhibitor.
前記アンジオテンシン受容体ブロッカーが、テルミサルタンを含む、医薬組成物。A pharmaceutical composition wherein the angiotensin receptor blocker comprises telmisartan.
前記アンジオテンシン（１－７）が、環状Ａｎｇ１－７を含む、医薬組成物。The pharmaceutical composition, wherein the angiotensin (1-7) comprises cyclic Ang 1-7.
前記ＨＭＧ－ＣｏＡ還元酵素阻害剤が、ロスバスタチンを含む、医薬組成物。A pharmaceutical composition, wherein the HMG-CoA reductase inhibitor comprises rosuvastatin.
前記アンジオテンシン受容体ブロッカー、前記アンジオテンシン（１－７）、前記ＨＭＧ－ＣｏＡ還元酵素阻害剤及び前記アンジオテンシン変換酵素阻害剤のうち少なくとも１つが、第２の抗酸化物質に連結され、at least one of the angiotensin receptor blocker, the angiotensin (1-7), the HMG-CoA reductase inhibitor, and the angiotensin converting enzyme inhibitor is linked to a second antioxidant;
前記第２の抗酸化物質が、テンポールを含む、医薬組成物。A pharmaceutical composition wherein the second antioxidant comprises tempol.
前記レニン－アンジオテンシン系モジュレーターが、前記第１の抗酸化物質に連結したピルフェニドンと、前記第２の抗酸化物質に連結した前記アンジオテンシン受容体ブロッカーとを含む、医薬組成物。A pharmaceutical composition, wherein the renin-angiotensin system modulator comprises pirfenidone linked to the first antioxidant and the angiotensin receptor blocker linked to the second antioxidant.
前記レニン－アンジオテンシン系モジュレーターが、前記第１の抗酸化物質に連結したピルフェニドンと、前記第２の抗酸化物質に連結した前記アンジオテンシン（１－７）とを含む、医薬組成物。A pharmaceutical composition, wherein the renin-angiotensin system modulator comprises pirfenidone linked to the first antioxidant and angiotensin(1-7) linked to the second antioxidant.
前記レニン－アンジオテンシン系モジュレーターが、前記第１の抗酸化物質に連結したピルフェニドンと、前記第２の抗酸化物質に連結した前記ＨＭＧ－ＣｏＡ還元酵素阻害剤とを含む、医薬組成物。A pharmaceutical composition, wherein the renin-angiotensin system modulator comprises pirfenidone linked to the first antioxidant and the HMG-CoA reductase inhibitor linked to the second antioxidant.
前記レニン－アンジオテンシン系モジュレーターが、前記第１の抗酸化物質に連結したピルフェニドンと、前記第２の抗酸化物質に連結した前記アンジオテンシン変換酵素阻害剤とを含む、医薬組成物。A pharmaceutical composition, wherein the renin-angiotensin system modulator comprises pirfenidone linked to the first antioxidant and the angiotensin converting enzyme inhibitor linked to the second antioxidant.
請求項１に記載の医薬組成物を、前記それを必要とする対象に投与することを含む、方法。A method comprising administering the pharmaceutical composition of claim 1 to a subject in need thereof.
請求項１に記載の医薬組成物を、前記それを必要とする対象に投与することを含む、方法。A method comprising administering the pharmaceutical composition of claim 1 to a subject in need thereof.
請求項１に記載の医薬組成物を、前記それを必要とする対象に投与することを含む、方法。A method comprising administering the pharmaceutical composition of claim 1 to a subject in need thereof.
請求項１に記載の医薬組成物を、前記それを必要とする対象に投与することを含む、方法。A method comprising administering the pharmaceutical composition of claim 1 to a subject in need thereof.
請求項１に記載の医薬組成物を、前記それを必要とする対象に投与することを含む、方法。A method comprising administering the pharmaceutical composition of claim 1 to a subject in need thereof.
請求項１に記載の医薬組成物を、前記それを必要とする対象に投与することを含む、方法。A method comprising administering the pharmaceutical composition of claim 1 to a subject in need thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063012981P | 2020-04-21 | 2020-04-21 | |
| US63/012,981 | 2020-04-21 | ||
| PCT/US2021/028357 WO2021216678A1 (en) | 2020-04-21 | 2021-04-21 | Renin-angiotensin system (ras) modulators for treatment of viral infections, pharmaceutical compositions including the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523247A JP2023523247A (en) | 2023-06-02 |
| JPWO2021216678A5 true JPWO2021216678A5 (en) | 2024-04-24 |
Family
ID=78270228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564370A Pending JP2023523247A (en) | 2020-04-21 | 2021-04-21 | RENNIN-ANGIOTENSIN SYSTEM (RAS) MODULATORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND THERAPEUTIC METHODS USING THE SAME FOR THE TREATMENT OF VIRAL INFECTIONS |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230338348A1 (en) |
| EP (1) | EP4138817A4 (en) |
| JP (1) | JP2023523247A (en) |
| KR (1) | KR20230028233A (en) |
| CA (1) | CA3176375A1 (en) |
| WO (1) | WO2021216678A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022251679A1 (en) * | 2021-05-27 | 2022-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nitroxide radicals for use as antiviral treatment for coronavirus infection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135422A1 (en) * | 2003-04-17 | 2006-06-22 | Moskowitz David W | Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE |
| EP1741702A1 (en) * | 2004-04-28 | 2007-01-10 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| CA2774239C (en) * | 2009-09-18 | 2017-06-20 | Georgetown University | Treatment for oxidative stress and/or hypertension |
| RU2537025C1 (en) * | 2013-05-28 | 2014-12-27 | Всеволод Иванович Киселев | Diindolylmethane drug preparation and using it for treating influenza and respiratory viral infections |
| US11311526B2 (en) * | 2016-03-31 | 2022-04-26 | Georgetown University | Radiation mitigator and method of use thereof |
-
2021
- 2021-04-21 US US17/996,678 patent/US20230338348A1/en active Pending
- 2021-04-21 JP JP2022564370A patent/JP2023523247A/en active Pending
- 2021-04-21 WO PCT/US2021/028357 patent/WO2021216678A1/en unknown
- 2021-04-21 KR KR1020227040450A patent/KR20230028233A/en active Search and Examination
- 2021-04-21 CA CA3176375A patent/CA3176375A1/en active Pending
- 2021-04-21 EP EP21792925.6A patent/EP4138817A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McKenney | Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks | |
| MX2007007843A (en) | Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same. | |
| WO2006083271A3 (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
| HUP0202461A2 (en) | Pharmaceutical formulations and use therof in the prevention of stroke, diabetes and/or congestive heart failure | |
| WO1995017899A2 (en) | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread | |
| RU2009107535A (en) | APPLICATION OF 3- (4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-IL) PIPERIDINE-2,6-DION FOR TREATMENT OF MANTLE ZONE CELLS | |
| Goyal et al. | Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review | |
| WO2006044968A3 (en) | Combination therapy for treating viral infections | |
| JP2019501886A5 (en) | ||
| Zhu et al. | Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial | |
| Bakris | Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker | |
| CA2633077A1 (en) | Solid-state form of amg 706 and pharmaceutical compositions thereof | |
| JPWO2021216678A5 (en) | ||
| WO2019129233A1 (en) | Use of parp inhibitor and oncolytic virus in preparing anti-tumor drug | |
| HUP0203682A2 (en) | Method for administering a phosphodiesterase 4 inhibitor | |
| Da Silva | Efficacy of Fixed-Dose Combination Therapy in the Treatment of Patients with Hypertension | |
| Moore | Topical microbicides become topical | |
| KR20210100539A (en) | Composition for preventing or treating cancer disease comprising immune checkpoint blockade and AMP-activated protein kinase activator | |
| RU2009149637A (en) | COMPOSITIONS APPLICABLE FOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE | |
| Dağlı et al. | Geriatrik pop ̧lasyonda hipertansiyon tedavisi | |
| US20060057620A1 (en) | Treatment of HIV infection | |
| Ker | Combination treatment for hypertension | |
| US20220387465A1 (en) | Compositions and methods for multi-use suppression and acquisition of viruses | |
| Thomopoulos et al. | 18.1 Antihypertensive Treatment and Heart Failure: Prevention of Recurrences or Prevention of New-Onset Heart Failure? | |
| Hansson et al. | The lower the better-PROGRESS of the concept |